Resverlogix Announces Participation In Upcoming Conferences
CALGARY, Sept. 12, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce its participation in the following industry conferences in the month of September.
- Rodman & Renshaw 18th Annual Global Investment Conference
Location: | New York, NY. |
Date: | September 13th, 2016 |
Presentation Time: | 2:10pm EDT |
Presenting: | Mr. Donald J. McCaffrey, President & Chief Executive Office |
Webcast link: |
- BioPharm America 9th Annual International Partnering Conference
Location: | Boston, MA. |
Date: | September 14th, 2016 |
Presentation Time: | 12:00pm EDT |
Presenting: | Mr. Kenneth Lebioda, Sr. VP Business & Corporate Development |
- 52nd European Association for the Study of Diabetes (EASD) Annual Meeting
Location: | Munich, Germany |
Date: | September 14th, 2016 |
Presentation Time: | 12:00pm CEST |
Presenting: | Dr. Norman Wong, Chief Scientific Officer |
Poster: | "Apabetalone (RVX-208) acts on epigenetics to lower Major Adverse Cardiovascular Events (MACE) in diabetes patients with atherosclerosis via microbiome activity" |
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
For further information please visit www.resverlogix.com.
Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
SOURCE Resverlogix Corp.
